Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Deep Dive into the Use of Real-World Registry Data as External Control Arms
While clinical registries are a valued source of longitudinal, real-world data, registries also provide expanded options for research and advancing randomized clinical trials. Understanding when and how to use registries in these use cases is quite nuanced and mandates a targeted approach and innovative expertise. In this video, we dive deep into the expanded use of registries as external control arms in clinical trials.
Watch this video and learn more:
- Challenges faced by biopharma companies conducting clinical trials when studying rare conditions.
- The purpose of a control population in traditional randomized controlled clinical trials.
- How hybrid control arms can improve the strength of control groups.
- How prospective registries serve as real-world control populations.
- How to minimize bias between populations or outcome measures across RCT control groups vs. real-world/hybrid controls.
Related Content
